Lineage Cell Therapeutics’ (LCTX) Buy Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) in a research note published on Friday,Benzinga reports. The brokerage currently has a $9.00 target price on the stock.

LCTX has been the subject of a number of other reports. Maxim Group decreased their price objective on shares of Lineage Cell Therapeutics from $5.00 to $3.00 and set a “buy” rating for the company in a research report on Friday, January 10th. D. Boral Capital reaffirmed a “buy” rating and issued a $2.00 price objective on shares of Lineage Cell Therapeutics in a report on Friday, January 3rd. Five analysts have rated the stock with a buy rating, According to MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $4.80.

Lineage Cell Therapeutics Stock Performance

Shares of LCTX opened at $0.60 on Friday. Lineage Cell Therapeutics has a twelve month low of $0.48 and a twelve month high of $1.61. The company has a market capitalization of $132.41 million, a price-to-earnings ratio of -5.01 and a beta of 1.18.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. Defender Capital LLC. increased its holdings in shares of Lineage Cell Therapeutics by 19.2% in the fourth quarter. Defender Capital LLC. now owns 5,963,348 shares of the company’s stock valued at $2,997,000 after purchasing an additional 961,150 shares during the last quarter. Raffles Associates LP boosted its holdings in shares of Lineage Cell Therapeutics by 3.4% during the 3rd quarter. Raffles Associates LP now owns 4,507,781 shares of the company’s stock worth $4,081,000 after buying an additional 150,000 shares during the period. Geode Capital Management LLC grew its stake in Lineage Cell Therapeutics by 2.3% in the 3rd quarter. Geode Capital Management LLC now owns 3,679,280 shares of the company’s stock valued at $3,331,000 after buying an additional 83,274 shares during the last quarter. State Street Corp raised its holdings in Lineage Cell Therapeutics by 1.8% in the 3rd quarter. State Street Corp now owns 2,608,352 shares of the company’s stock valued at $2,361,000 after acquiring an additional 45,483 shares during the period. Finally, MAI Capital Management lifted its position in Lineage Cell Therapeutics by 2.2% during the third quarter. MAI Capital Management now owns 1,674,679 shares of the company’s stock worth $1,516,000 after acquiring an additional 35,907 shares during the last quarter. 62.47% of the stock is owned by institutional investors and hedge funds.

Lineage Cell Therapeutics Company Profile

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.